Category

News
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple myeloma. Although stem cell mobilization is successful in the majority of patients with multiple myeloma, the use of granulocyte colony-stimulating factor (G-CSF) used alone is associated with up to a 10% failure rate, Kumar explains....
Continue Reading
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according to data from a Phase 3 trial. “There is a strong need for additional maintenance treatments for multiple myeloma, where currently approved options are limited,” Meletios Dimopoulos, MD, the trial’s...
Continue Reading
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment regimen combining Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone on the Pharmaceutical Benefits Scheme (PBS). Known as triplet therapy, each drug in the combination has a different mechanism of action to kill myeloma cells, and all work...
Continue Reading
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have unveiled the first in silico multiple myeloma patient. Called Gemini, the in silico multiple myeloma patient is a computer model of disease progression and drug response at the individual patient level. The company says Gemini has multiple...
Continue Reading
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.
Continue Reading
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin...
Continue Reading
A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were accurately identified in a genomic test of bone marrow tissue, according to a study led by researchers at the Dana-Farber Cancer Institute and published in the Journal of Clinical Oncology.1,2 Patients identified with these alterations can be closely...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This study evaluated addition of daratumumab (D) to RVd in ASCTeligible NDMM patients. Patients (N=207) were randomized...
Continue Reading
Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more vulnerable than those in clinical trials. A retrospective review has reported data from 74 patients at three Queensland hospitals who had newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation who were...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. Multiple myeloma (MM) is the third most common hematologic malignancy worldwide, characterized by excessive proliferation of monoclonal plasma cells. The development of novel anti-MM agents has expanded treatment options for MM patients and improved out-comes. Despite recent treatment advances, MM remains incurable, with...
Continue Reading
1 2 3 24

Floor 7, 90 The Terrace
Wellington Central
New Zealand